达沙替尼
临床试验
疾病
下载
医学
肾脏疾病
槲皮素
内科学
透明度(行为)
内分泌学
计算机科学
生物
万维网
生物化学
计算机安全
酪氨酸激酶
受体
抗氧化剂
作者
LaTonya J. Hickson,Larissa G. P. Langhi Prata,Shane A. Bobart,Tamara K. Evans,Nino Giorgadze,Shahrukh Khurshid Hashmi,Sandra M. Herrmann,Michael D. Jensen,Qingyi Jia,Kyra L. Jordan,Todd Andrew Kellogg,Sundeep Khosla,Daniel M. Koerber,Anthony B. Lagnado,Donna K. Lawson,Nathan K. LeBrasseur,Lilach O. Lerman,Kathleen M. McDonald,Travis J. McKenzie,João F. Passos
出处
期刊:EBioMedicine
[Elsevier BV]
日期:2020-01-23
卷期号:52: 102595-102595
被引量:69
标识
DOI:10.1016/j.ebiom.2019.12.004
摘要
In this article, a re-analysis of the raw data has been conducted, which means that some conclusions presented in the paper have changed. The authors have written a Corrigendum which is appended (Appendix 1). In the interests of transparency, they have included de-identified data from the original article in Appendix 2. Download .docx (.54 MB) Help with docx files Download .xlsx (.01 MB) Help with xlsx files Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease“Hit-and-run” treatment with senolytics, which in the case of D + Q have elimination half-lives <11 h, significantly decreases senescent cell burden in humans. Full-Text PDF Open Access
科研通智能强力驱动
Strongly Powered by AbleSci AI